Recon: Ono set to buy Deciphera for $2.4B; FDA approves X4’s ultra-rare immunodeficiency disease therapy
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States